With only two anti-psychotic drugs currently approved for younger patients, a positive decision for the three drugs would significantly increase competition in the space
- and expand sales of products that already are big sellers.
Anti-psychotic drugs were the top-selling group of prescription medications in the U.S. last year with sales of $14.6 billion, according to the health care analysis firm.
The FDA released its review of the three drugs ahead of a meeting Tuesday where outside experts will weigh in on the drugs' risks and benefits. The agency is not required to follow the group's advice, though it usually does.
FDA reviewers said Friday they were wary of exposing youngsters to the drugs' side effects, including weight gain and high blood sugar, "because they may be exposed for many decades."
"These risks are of particular concern in pediatric patients because of the lifelong nature of these disorders," FDA director for psychiatric products, Dr. Thomas Laughren, wrote in documents posted online.
Many doctors already prescribe the medications to children and adolescents, although regulators have not officially cleared that use. Physicians are free to prescribe medicines as they see fit, though companies can only promote them for FDA-approved indications.
AstraZeneca and Lilly are seeking permission to market their drugs for adolescents with schizophrenia and bipolar mania, also called manic depressive disorder. Pfizer is seeking a pediatric bipolar disorder indication for its drug.
FDA drug reviewers noted that the "safety profile of the pediatric population is very similar compared to that of the adult population." And while there were no side effects unique to younger patients, there were differences in the frequency of the effects compared with adults.
In schizophrenia studies of Lilly's Zyprexa, more than 30 percent of adolescents gained weight, compared with just 6 percent of adults. On average, adolescents gained nearly 10 pounds, compared with 6 pounds for adults.
